Medicaid Expansion and Buprenorphine Dispensing in Early vs Recent Expansion States
In this cross-sectional study using contemporary data and methods, post-2018 Medicaid expansions were associated with substantial increases in buprenorphine treatment, particularly in high-need states operating under newer prescribing regulations. These findings underscore Medicaid expansion's role in improving opioid use disorder treatment access and can inform state and federal efforts to expand evidence-based care.
Authors
- Jennifer Miles (ORCID: https://orcid.org/0000-0002-6891-9756)
- Hillary Samples (ORCID: https://orcid.org/0000-0001-5773-3705)
- Kosali Simon (ORCID: https://orcid.org/0000-0002-3231-1466)
- Nicole Siegal
- Sumedha Gupta (ORCID: https://orcid.org/0000-0001-7924-4160)
- Stephen Crystal
Institutions
- Rutgers, The State University of New Jersey (US)
- Indiana University Health (US)
- National Bureau of Economic Research (US)
- Johnson University (US)
- Indiana University Bloomington (US)
- Indiana University Indianapolis (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.59803
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00